Search

Your search keyword '"DiNardo, Courtney"' showing total 3,482 results
Start Over Author "DiNardo, Courtney"
3,482 results on '"DiNardo, Courtney"'

1. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

Author

Montalban-Bravo, Guillermo, Rodriguez-Sevilla, Juan Jose, Swanson, David Michael, Kanagal-Shamanna, Rashmi, Hammond, Danielle, Chien, Kelly, Sasaki, Koji, Jabbour, Elias, DiNardo, Courtney, Takahashi, Koichi, Short, Nicholas, Issa, Ghayas C., Pemmaraju, Naveen, Kadia, Tapan, Ravandi, Farhad, Daver, Naval, Borthakur, Gautam, Loghavi, Sanam, Pierce, Sherry, Bueso-Ramos, Carlos, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

5. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

Author

Pollyea, Daniel A, Pratz, Keith W, Wei, Andrew H, Pullarkat, Vinod, Jonas, Brian A, Recher, Christian, Babu, Sunil, Schuh, Andre C, Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, and DiNardo, Courtney D

Subjects
Cancer, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase III as Topic, Clinical Trials, Phase I as Topic, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.Patients and methodsWe analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.ResultsPatients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.ConclusionsIn poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

Published
2022

6. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Author

DiNardo, Courtney D., Roboz, Gail J., Watts, Justin M., Madanat, Yazan F., Prince, Gabrielle T., Baratam, Praneeth, de Botton, Stéphane, Stein, Anthony, Foran, James M., Arellano, Martha L., Sallman, David A., Hossain, Mohammad, Marchione, Dylan M., Bai, Xiaofei, Patel, Prapti A., Kapsalis, Stephanie M., Garcia-Manero, Guillermo, and Fathi, Amir T.

Published
2024
Full Text
View/download PDF

7. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Author

Bataller, Alex, Gener-Ricos, Georgina, Almanza-Huante, Emmanuel, Chien, Kelly S., Urrutia, Samuel, Bazinet, Alexandre, Rodriguez-Sevilla, Juan Jose, Hammond, Danielle, Sasaki, Koji, Takahashi, Koichi, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Kadia, Tapan M., Kanagal-Shamanna, Rashmi, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and Montalban-Bravo, Guillermo

Published
2024
Full Text
View/download PDF

11. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Author

Fiskus, Warren, Piel, Jessica, Collins, Mike, Hentemann, Murphy, Cuglievan, Branko, Mill, Christopher P., Birdwell, Christine E., Das, Kaberi, Davis, John A., Hou, Hanxi, Jain, Antrix, Malovannaya, Anna, Kadia, Tapan M., Daver, Naval, Sasaki, Koji, Takahashi, Koichi, Hammond, Danielle, Reville, Patrick K., Wang, Jian, Loghavi, Sanam, Sen, Rwik, Ruan, Xinjia, Su, Xiaoping, Flores, Lauren B., DiNardo, Courtney D., and Bhalla, Kapil N.

Published
2024
Full Text
View/download PDF

14. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Author

Bazinet, Alexandre, Garcia-Manero, Guillermo, Short, Nicholas, Alvarado, Yesid, Bataller, Alex, Abuasab, Tareq, Islam, Rabiul, Montalbano, Kathryn, Issa, Ghayas, Maiti, Abhishek, Yilmaz, Musa, Jain, Nitin, Masarova, Lucia, Kornblau, Steven, Jabbour, Elias, Montalban-Bravo, Guillermo, Rausch, Caitlin R, Pierce, Sherry, DiNardo, Courtney D, Kadia, Tapan, Daver, Naval, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

15. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Author

Hammond, Danielle, Loghavi, Sanam, Wang, Sa A., Konopleva, Marina Y., Kadia, Tapan M., Daver, Naval G., Ohanian, Maro, Issa, Ghayas C., Alvarado, Yesid, Short, Nicholas J., Sasaki, Koji, Pemmaraju, Naveen, Montalban-Bravo, Guillermo, Lachowiez, Curtis A., Maiti, Abhishek, Garcia-Manero, Guillermo, Jabbour, Elias J., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Pierce, Sherry R., Kantarjian, Hagop M., and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

16. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Author

Senapati, Jayastu, Muftuoglu, Muharrem, Ishizawa, Jo, Abbas, Hussein A., Loghavi, Sanam, Borthakur, Gautam, Yilmaz, Musa, Issa, Ghayas C., Dara, Samuel I., Basyal, Mahesh, Li, Li, Naqvi, Kiran, Pourebrahim, Rasoul, Jabbour, Elias J., Kornblau, Steven M., Short, Nicholas J., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Ravandi, Farhad, Khoury, Joseph, Daver, Naval, Kantarjian, Hagop M., Andreeff, Michael, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

19. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Author

Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Recher, Christian, Schuh, Andre C, Thirman, Michael J, Garcia, Jacqueline S, DiNardo, Courtney D, Vorobyev, Vladimir, Fracchiolla, Nicola S, Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, and Döhner, Hartmut

Subjects
Clinical Research, Prevention, Cancer, Hematology, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Prognosis, Remission Induction, Sulfonamides, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThere is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10-3 in the VIALE-A trial.MethodsThe patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10-3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS.ResultsOne hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10-3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10-3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10-3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10-3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10-3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001).ConclusionPatients who achieved CRc and MRD < 10-3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10-3.

Published
2022

20. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Author

Pratz, Keith W, Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A, Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C, DiNardo, Courtney D, Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H, Bui, Cat N, Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, and Fiedler, Walter

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Cancer, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Cytarabine, Fatigue, Humans, Leukemia, Myeloid, Acute, Quality of Life, Sulfonamides, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

Published
2022

21. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Author

Bataller, Alex, Bazinet, Alexandre, DiNardo, Courtney D., Maiti, Abhishek, Borthakur, Gautam, Daver, Naval G., Short, Nicholas J., Jabbour, Elias J., Issa, Ghayas C., Pemmaraju, Naveen, Yilmaz, Musa, Montalban-Bravo, Guillermo, Takahashi, Koichi, Loghavi, Sanam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., and Kadia, Tapan M.

Published
2024
Full Text
View/download PDF

23. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia

Author

Yeh, Jason, Pasvolsky, Oren, Saliba, Rima M., Figgins, Bradley, Wang, Christopher, Fang, Zhou, Ahmed, Sairah, Yilmaz, Musa, Daver, Naval, Ravandi, Farhad, DiNardo, Courtney, Short, Nicholas J., Kadia, Tapan, Al-Atrash, Gheath, Daher, May, Costa, David Marin, Popat, Uday, Champlin, Richard, Shpall, Elizabeth, and Oran, Betül

Published
2024
Full Text
View/download PDF

27. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Author

Senapati, Jayastu, Urrutia, Samuel, Loghavi, Sanam, Short, Nicholas J., Issa, Ghayas C., Maiti, Abhishek, Abbas, Hussein A., Daver, Naval G., Pemmaraju, Naveen, Pierce, Sherry, Chien, Kelly S., Sasaki, Koji, Kadia, Tapan M., Hammond, Danielle E., Borthakur, Gautam, Patel, Keyur, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

28. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results

Author

Sasaki, Koji, Morita, Kiyomi, Kantarjian, Hagop, Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Wierda, William, Daver, Naval, Takahashi, Koichi, DiNardo, Courtney, Bravo, Guillermo Montalban, Issa, Ghayas C., Pierce, Sherry A., Soltysiak, Kelly A., Tingen, Martha S., and Cortes, Jorge E.

Published
2023
Full Text
View/download PDF

29. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Author

Homan, Claire C., Drazer, Michael W., Yu, Kai, Lawrence, David M., Feng, Jinghua, Arriola-Martinez, Luis, Pozsgai, Matthew J., McNeely, Kelsey E., Ha, Thuong, Venugopal, Parvathy, Arts, Peer, King-Smith, Sarah L., Cheah, Jesse, Armstrong, Mark, Wang, Paul, Bödör, Csaba, Cantor, Alan B., Cazzola, Mario, Degelman, Erin, DiNardo, Courtney D., Duployez, Nicolas, Favier, Remi, Fröhling, Stefan, Rio-Machin, Ana, Klco, Jeffery M., Krämer, Alwin, Kurokawa, Mineo, Lee, Joanne, Malcovati, Luca, Morgan, Neil V., Natsoulis, Georges, Owen, Carolyn, Patel, Keyur P., Preudhomme, Claude, Raslova, Hana, Rienhoff, Hugh, Ripperger, Tim, Schulte, Rachael, Tawana, Kiran, Velloso, Elvira, Yan, Benedict, Kim, Erika, Sood, Raman, Hsu, Amy P., Holland, Steven M., Phillips, Kerry, Poplawski, Nicola K., Babic, Milena, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Lewis, Ian D., Cooney, Julian, Susman, Rachel, Fox, Lucy C., Blombery, Piers, Singhal, Deepak, Hiwase, Devendra, Phipson, Belinda, Schreiber, Andreas W., Hahn, Christopher N., Scott, Hamish S., Liu, Paul, Godley, Lucy A., and Brown, Anna L.

Published
2023
Full Text
View/download PDF

30. Hematopoiesis under telomere attrition at the single-cell resolution

Author

Thongon, Natthakan, Ma, Feiyang, Santoni, Andrea, Marchesini, Matteo, Fiorini, Elena, Rose, Ashley, Adema, Vera, Ganan-Gomez, Irene, Groarke, Emma M, Gutierrez-Rodrigues, Fernanda, Chen, Shuaitong, Lockyer, Pamela, Schneider, Sarah, Bueso-Ramos, Carlos, Montalban-Bravo, Guillermo, Class, Caleb A, Soltysiak, Kelly A, Pellegrini, Matteo, Sahin, Ergun, Bertuch, Alison A, DiNardo, Courtney D, Garcia-Manero, Guillermo, Young, Neal S, Dwyer, Karen, and Colla, Simona

Subjects
Genetics, Stem Cell Research - Nonembryonic - Non-Human, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Regenerative Medicine, Underpinning research, 1.1 Normal biological development and functioning, Inflammatory and immune system, Animals, Bone Marrow Failure Disorders, Cell Self Renewal, Cellular Reprogramming, Hematopoiesis, Hematopoietic Stem Cells, Humans, Interferons, Megakaryocytes, Mice, Nuclear Proteins, Oligodeoxyribonucleotides, Phosphoproteins, Signal Transduction, Single-Cell Analysis, Telomere, Telomere Shortening
Abstract

The molecular mechanisms that drive hematopoietic stem cell functional decline under conditions of telomere shortening are not completely understood. In light of recent advances in single-cell technologies, we sought to redefine the transcriptional and epigenetic landscape of mouse and human hematopoietic stem cells under telomere attrition, as induced by pathogenic germline variants in telomerase complex genes. Here, we show that telomere attrition maintains hematopoietic stem cells under persistent metabolic activation and differentiation towards the megakaryocytic lineage through the cell-intrinsic upregulation of the innate immune signaling response, which directly compromises hematopoietic stem cells' self-renewal capabilities and eventually leads to their exhaustion. Mechanistically, we demonstrate that targeting members of the Ifi20x/IFI16 family of cytosolic DNA sensors using the oligodeoxynucleotide A151, which comprises four repeats of the TTAGGG motif of the telomeric DNA, overcomes interferon signaling activation in telomere-dysfunctional hematopoietic stem cells and these cells' skewed differentiation towards the megakaryocytic lineage. This study challenges the historical hypothesis that telomere attrition limits the proliferative potential of hematopoietic stem cells by inducing apoptosis, autophagy, or senescence, and suggests that targeting IFI16 signaling axis might prevent hematopoietic stem cell functional decline in conditions affecting telomere maintenance.

Published
2021

31. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Author

Short, Nicholas J., Ong, Faustine, Ravandi, Farhad, Nogueras-Gonzalez, Graciela, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Borthakur, Gautam, Oran, Betul, Al-Atrash, Gheath, Mehta, Rohtesh, Jabbour, Elias J., Yilmaz, Musa, Issa, Ghayas C, Maiti, Abhishek, Champlin, Richard E, Kantarjian, Hagop, Shpall, Elizabeth J, and Popat, Uday

Published
2023
Full Text
View/download PDF

35. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Author

DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, and Garcia-Manero, Guillermo

Published
2023
Full Text
View/download PDF

36. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Senapati, Jayastu, Jain, Nitin, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Pemmaraju, Naveen, Wierda, William, Garcia-Manero, Guillermo, Montalban Bravo, Guillermo, Sasaki, Koji, Kadia, Tapan M, Khoury, Joseph, Wang, Sa A, Haddad, Fadi G, Jacob, Jovitta, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2023
Full Text
View/download PDF

37. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Published
2023
Full Text
View/download PDF

38. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

39. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

40. Effect of Digital Health Coaching on Self-Efficacy and Patient Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial

Author

Marvin-Peek, Jennifer, primary, Shelton, Valerie, additional, Brassil, Kelly, additional, Fellman, Bryan, additional, Barr, Austin, additional, Chien, Kelly Sharon, additional, Hammond, Danielle, additional, Swaminathan, Mahesh, additional, Jain, Nitin, additional, Wierda, William, additional, Ferrajoli, Alessandra, additional, and DiNardo, Courtney, additional

Published
2024
Full Text
View/download PDF

41. TP53 Y220C mutations in patients with myeloid malignancies

Author

Gener-Ricos, Georgina, primary, Bewersdorf, Jan P., additional, Loghavi, Sanam, additional, Bataller, Alex, additional, Goldberg, Aaron D., additional, Famulare, Christopher, additional, Takahashi, Koichi, additional, Issa, Ghayas C., additional, Borthakur, Gautam, additional, Kadia, Tapan M., additional, Short, Nicholas J., additional, Senapati, Jayastu, additional, Carter, Bing Z., additional, Patel, Keyur P., additional, Kantarjian, Hagop, additional, Andreeff, Michael, additional, Stein, Eytan M., additional, and DiNardo, Courtney D., additional

Published
2024
Full Text
View/download PDF

42. Detection of PNH clones can aid in the distinction of aplastic anemia vs inherited BM failure syndromes: a single center experience and review of the literature.

Author

Nasnas, Patrice, primary, Ling, Jianhua, additional, Gerstein, Yoheved, additional, Wang, Sa A., additional, Loghavi, Sanam, additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Senapati, Jayastu, additional, Pemmaraju, Naveen, additional, Corredor, Jessie, additional, Pierce, Sherry, additional, Roth, Michael, additional, Ravandi, Farhad, additional, Cuglievan, Branko, additional, Kadia, Tapan, additional, and DiNardo, Courtney D, additional

Published
2024
Full Text
View/download PDF

43. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.

Author

Kugler, Eitan, primary, Dasdemir, Enes, additional, Wang, Bofei, additional, Bataller, Alex, additional, Dinardo, Courtney Denton, additional, Daver, Naval Guastad, additional, Yilmaz, Musa, additional, Short, Nicholas James, additional, Kadia, Tapan M., additional, Sasaki, Koji, additional, Bazinet, Alexandre, additional, Pierce, Sherry, additional, Reville, Patrick Kevin, additional, Ravandi-Kashani, Farhad, additional, and Abbas, Hussein, additional

Published
2024
Full Text
View/download PDF

44. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

Author

Jen, Wei Ying, primary, Takahashi, Koichi, additional, Loghavi, Sanam, additional, Kadia, Tapan M., additional, Daver, Naval Guastad, additional, Xiao, Lianchun, additional, Short, Nicholas James, additional, Borthakur, Gautam, additional, Issa, Ghayas C., additional, Pemmaraju, Naveen, additional, Reville, Patrick Kevin, additional, Bravo, Guillermo Montalban, additional, Yilmaz, Musa, additional, Garcia-Manero, Guillermo, additional, Ravandi-Kashani, Farhad, additional, Konopleva, Marina, additional, Mullin, Jillian K, additional, Pierce, Sherry, additional, Kantarjian, Hagop M., additional, and Dinardo, Courtney Denton, additional

Published
2024
Full Text
View/download PDF

45. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.

Author

Urrutia, Samuel, primary, Kantarjian, Hagop M., additional, Ravandi-Kashani, Farhad, additional, Jabbour, Elias, additional, Kanagal-Shamanna, Rashmi, additional, Loghavi, Sanam, additional, Patel, Keyur P., additional, Montalban-Bravo, Guillermo, additional, Short, Nicholas James, additional, Daver, Naval Guastad, additional, Borthakur, Gautam, additional, Dinardo, Courtney Denton, additional, Kadia, Tapan M., additional, Masarova, Lucia, additional, Bose, Prithviraj, additional, Pemmaraju, Naveen, additional, Garcia-Manero, Guillermo, additional, and Sasaki, Koji, additional

Published
2024
Full Text
View/download PDF

46. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.

Author

Bazinet, Alexandre, primary, Dinardo, Courtney Denton, additional, Arani, Naszrin, additional, Bataller, Alex, additional, Rausch, Caitlin R, additional, Maiti, Abhishek, additional, Swaminathan, Mahesh, additional, Daver, Naval Guastad, additional, Kadia, Tapan M., additional, Ravandi-Kashani, Farhad, additional, Kantarjian, Hagop M., additional, Chraibi, Samy, additional, Decroocq, Justine, additional, Pascal, Laurent, additional, Lebon, Delphine, additional, Bonnet, Sarah, additional, Gauthier, Nicolas, additional, Pages, Arnaud, additional, De Botton, Stéphane, additional, and Willekens, Christophe, additional

Published
2024
Full Text
View/download PDF

47. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes

Author

Kadia, Tapan M., primary, Huang, Meixian, additional, Pemmaraju, Naveen, additional, Abbas, Hussein A., additional, Ly, Christopher, additional, Masarova, Lucia, additional, Yilmaz, Musa, additional, Lyu, Mi-Ae, additional, Zeng, Ke, additional, Sadeghi, Tara, additional, Cook, Robin, additional, DiNardo, Courtney D., additional, Daver, Naval, additional, Issa, Ghayas C., additional, Jabbour, Elias, additional, Borthakur, Gautam, additional, Jain, Nitin, additional, Garcia-Manero, Guillermo, additional, Parmar, Simrit, additional, Flowers, Christopher, additional, Kantarjian, Hagop, additional, and Verstovsek, Srdan, additional

Published
2024
Full Text
View/download PDF

48. Clonal evolution of hematopoietic stem cells after cancer chemotherapy

Author

Uryu, Hidetaka, primary, Saeki, Koichi, additional, Haeno, Hiroshi, additional, Kapadia, Chiraag Deepak, additional, Furudate, Ken, additional, Nangalia, Jyoti, additional, Chapman, Michael Spencer, additional, Zhao, Li, additional, Hsu, Joanne I, additional, Zhao, Chong, additional, Chen, Shujuan, additional, Tanaka, Tomoyuki, additional, Li, Zongrui, additional, Yang, Hui, additional, DiNardo, Courtney, additional, Daver, Naval, additional, Pemmaraju, Naveen, additional, Jain, Nitin, additional, Ravandi, Farhad, additional, Zhang, Jianhua, additional, Song, Xingzhi, additional, Thompson, Erika, additional, Tang, Hongli, additional, Little, Latasha, additional, Gumbs, Curtis, additional, Orlowski, Robert, additional, Qazilbash, Muzaffar, additional, Bhalla, Kapil, additional, Colla, Simona, additional, Kantarjian, Hagop, additional, Shamanna, Rashmi Kanagal, additional, Bueso-Ramos, Carlos, additional, Nakada, Daisuke, additional, Futreal, P Andrew, additional, Shpall, Elizabeth, additional, Goodell, Margaret, additional, Garcia-Manero, Guillermo, additional, and Takahashi, Koichi, additional

Published
2024
Full Text
View/download PDF

50. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications

Author

Abuasab, Tareq, primary, Borthakur, Gautam, additional, Kanagal‐Shamanna, Rashmi, additional, Masarova, Lucia, additional, Patel, Keyur, additional, Takahashi, Koichi, additional, Bose, Prithviraj, additional, Villarreal, John, additional, Pierce, Sherry, additional, Kadia, Tapan, additional, Garcia‐Manero, Guillermo, additional, Short, Nicholas J., additional, DiNardo, Courtney, additional, Daver, Naval, additional, Ravandi, Farhad, additional, Kantarjian, Hagop, additional, Verstovsek, Srdan, additional, and Yilmaz, Musa, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results